See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Liberation Day
Natural Disasters
Donald Trump
Trade War
Social Media
Stock Markets
Soccer
Democratic Party
Republican Party
US Economy
Artificial Intelligence
Published • loading... • Updated

Guggenheim Reiterates "Buy" Rating for Compass Therapeutics (NASDAQ:CMPX)

Summary by marketbeat.com
Guggenheim reissued a "buy" rating and issued a $12.00 price target on shares of Compass Therapeutics in a report on Wednesday.

2 Articles

All
Left
Center
1
Right
marketbeat.commarketbeat.com
Center

Guggenheim Reiterates "Buy" Rating for Compass Therapeutics (NASDAQ:CMPX)

Guggenheim reissued a "buy" rating and issued a $12.00 price target on shares of Compass Therapeutics in a report on Wednesday.

Read Full Article
reporter.amreporter.am

Phathom Pharmaceuticals (NASDAQ:PHAT) Given Buy Rating at Guggenheim

Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at Guggenheim in a research report issued on Wednesday,Benzinga reports. PHAT has been the topic of several other research reports. Cantor Fitzgerald upgraded shares of Phathom Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, February 25th. Craig […]

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

reporter.am broke the news in on Friday, April 4, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Stock Markets

Stock Markets

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal